Nemonoxacin

Nemonoxacin is a novel non-fluorinated quinolone antibiotic, which is currently under development for the treatment of various bacterial infections, particularly those caused by Gram-positive bacteria. It is a broad-spectrum antibiotic that is effective against both Gram-positive and Gram-negative bacteria.

Etymology

The name "Nemonoxacin" is derived from the Greek words "nemo" meaning "nobody" and "nox" meaning "night". This could possibly refer to the antibiotic's ability to eliminate bacteria, thus "nobody" (no bacteria) "night" (darkness, or illness).

Mechanism of Action

Nemonoxacin works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV, which are necessary for bacterial DNA replication, transcription, repair, and recombination. This results in the death of the bacteria.

Clinical Trials

Nemonoxacin has undergone Phase II and III clinical trials for the treatment of community-acquired pneumonia and diabetic foot infections. The results of these trials have shown that Nemonoxacin is as effective as other quinolone antibiotics, but with fewer side effects.

Side Effects

The most common side effects of Nemonoxacin include nausea, vomiting, diarrhea, and abdominal pain. Less common side effects include headache, dizziness, and rash.

Resistance

Resistance to Nemonoxacin is less common than resistance to other quinolone antibiotics. This is due to the fact that Nemonoxacin is a non-fluorinated quinolone, which makes it less likely to be affected by bacterial resistance mechanisms.

Related Terms

• Quinolone
• Antibiotic
• Gram-positive bacteria
• Gram-negative bacteria
• DNA gyrase
• Topoisomerase IV

Nemonoxacin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia